Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761955 | 0.78 | CCR5 (0.39) | CCR5HTR2AHTR2CSIGMAR1 | |
| SCHEMBL7675854 | 0.72 | DRD4 (0.44) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL10300869 | 0.71 | PLCG1 (0.36) | CCR5 | |
| SCHEMBL3287322 | 0.70 | HRH3 (0.54) | CCR5HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23508644 | 0.69 | SIGMAR1 (0.49) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL12991140 | 0.69 | SIGMAR1 (0.60) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL2743258 | 0.68 | SIGMAR1 (0.67) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL21845237 | 0.68 | SLC10A2 (0.35) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14508463 | 0.68 | SIGMAR1 (0.51) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL9927232 | 0.67 | DRD4 (0.50) | HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | CCR5 4565/4885HTR2A 4769/4885HTR2C 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.